Volume 9 Supplement 1

Differential use of CCR5 vs. CXCR4 by HIV-1. Pathogenic, Translational and Clinical Open Questions

Reviews

Edited by Guido Poli and Luigi Buonaguro

  1. Review

    Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies

    The human immunodeficiency virus type 1 (HIV-1) external envelope glycoprotein gp120 presents conserved binding sites for binding to the primary virus receptor CD4 as well as the major HIV chemokine coreceptor...

    Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro and Luigi Buonaguro

    Journal of Translational Medicine 2011 9(Suppl 1):S1

    Published on: 27 January 2011

  2. Review

    HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV

    It is well established that HIV-1 infection typically involves an interaction between the viral envelope protein gp120/41 and the CD4 molecule followed by a second interaction with a chemokine receptor, usuall...

    Claudia Cicala, James Arthos and Anthony S Fauci

    Journal of Translational Medicine 2011 9(Suppl 1):S2

    Published on: 27 January 2011

  3. Review

    Natural anti-CCR5 antibodies in HIV-infection and -exposure

    Natural antibodies constitute a first-line of defence against pathogens; they may also play other roles in immune regulation and homeostasis, through their ability to bind host antigens, surface molecules and ...

    Lucia Lopalco

    Journal of Translational Medicine 2011 9(Suppl 1):S4

    Published on: 27 January 2011

  4. Review

    Clinical significance of HIV-1 coreceptor usage

    The identification of phenotypically distinct HIV-1 variants with different prevalence during the progression of the disease has been one of the earliest discoveries in HIV-1 biology, but its relevance to AIDS...

    Hanneke Schuitemaker, Angélique B van 't Wout and Paolo Lusso

    Journal of Translational Medicine 2011 9(Suppl 1):S5

    Published on: 27 January 2011

  5. Review

    Selective transmission of R5 HIV-1 variants: where is the gatekeeper?

    To enter target cells HIV-1 uses CD4 and a coreceptor. In vivo the coreceptor function is provided either by CCR5 (for R5) or CXCR4 (for X4 HIV-1). Although both R5 and X4 HIV-1 variants are present in body fluid...

    Jean-Charles Grivel, Robin J Shattock and Leonid B Margolis

    Journal of Translational Medicine 2011 9(Suppl 1):S6

    Published on: 27 January 2011

  6. Review

    Coreceptor use in nonhuman primate models of HIV infection

    SIV or SHIV infection of nonhuman primates (NHP) has been used to investigate the impact of coreceptor usage on the composition and dynamics of the CD4+ T cell compartment, mechanisms of disease induction and ...

    Silvana Tasca Sina, Wuze Ren and Cecilia Cheng-Mayer

    Journal of Translational Medicine 2011 9(Suppl 1):S7

    Published on: 27 January 2011

  7. Review

    Asymmetric HIV-1 co-receptor use and replication in CD4+ T lymphocytes

    Susceptibility to infection by the human immunodeficiency virus type-1 (HIV-1), both in vitro and in vivo, requires the interaction between its envelope (Env) glycoprotein gp120 Env and the primary receptor (R), ...

    Samanta A Mariani, Elisa Vicenzi and Guido Poli

    Journal of Translational Medicine 2011 9(Suppl 1):S8

    Published on: 27 January 2011

  8. Review

    Clinical use of CCR5 inhibitors in HIV and beyond

    Since the discovery of CCR5 as a coreceptor for HIV entry, there has been interest in blockade of the receptor for treatment and prevention of HIV infection. Although several CCR5 antagonists have been evaluat...

    Bruce L Gilliam, David J Riedel and Robert R Redfield

    Journal of Translational Medicine 2011 9(Suppl 1):S9

    Published on: 27 January 2011